GlobeNewswire: Equillium, Inc. Contains the last 10 of 76 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:50:29ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/07/12/2261480/0/en/Equillium-Announces-Plans-to-Initiate-Phase-3-Pivotal-Study-of-Itolizumab-in-First-line-Treatment-of-Acute-Graft-Versus-Host-Disease-Following-End-of-Phase-1-Meeting-with-the-FDA.html?f=22&fvtc=4&fvtv=51062Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA2021-07-12T20:01:00Z<![CDATA[Single pivotal Phase 3 study in acute graft-versus-host disease tosupport filing of biologics license application]]>https://www.globenewswire.com/news-release/2021/06/11/2245797/0/en/Equillium-Announces-Positive-Topline-Results-from-the-EQUATE-Study-in-First-line-Treatment-of-Acute-Graft-Versus-Host-Disease.html?f=22&fvtc=4&fvtv=51062Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease2021-06-11T11:00:00Z<![CDATA[Itolizumab continues to demonstrate favorable safety and efficacy profile]]>https://www.globenewswire.com/news-release/2021/06/10/2245170/0/en/Equillium-Presents-Data-on-Target-Engagement-and-Modulation-of-CD6-on-T-Cells-with-Itolizumab-at-the-International-Society-for-Advancement-of-Cytometry.html?f=22&fvtc=4&fvtv=51062Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry2021-06-10T12:00:00Z<![CDATA[Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases]]>https://www.globenewswire.com/news-release/2021/06/09/2244328/0/en/Equillium-to-Present-at-the-JMP-Securities-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=51062Equillium to Present at the JMP Securities Life Sciences Conference2021-06-09T12:00:00Z<![CDATA[LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the JMP Securities Life Sciences Conference, a virtual investor event, taking place June 16 and 17, 2021.]]>https://www.globenewswire.com/news-release/2021/06/07/2242674/0/en/Equillium-to-Collaborate-with-Oxford-University-and-Kennedy-Institute-of-Rheumatology-to-Investigate-Role-of-the-CD6-ALCAM-Pathway-and-Itolizumab-in-Rheumatic-Diseases.html?f=22&fvtc=4&fvtv=51062Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases2021-06-07T12:00:00Z<![CDATA[LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced a translational research collaboration with the Kennedy Institute for Rheumatology and the Sir William Dunn School of Pathology, University of Oxford. The research collaboration will study how CD6 monoclonal antibodies, such as itolizumab, modulate T cell responses and explore the role of the CD6-ALCAM pathway in rheumatic diseases. CD6 is a co-stimulatory receptor, predominantly expressed on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presenting cells and various epithelial and endothelial tissues. The CD6-ALCAM pathway plays an integral role in modulating T cell activation, proliferation, differentiation and trafficking and is believed to play a central role in many autoimmune disorders.]]>https://www.globenewswire.com/news-release/2021/06/03/2241251/0/en/Equillium-to-Host-Conference-Call-Following-Presentation-of-Data-from-the-EQUATE-Study-in-Acute-Graft-Versus-Host-Disease-at-the-EHA2021-Virtual-Congress-of-the-European-Hematology.html?f=22&fvtc=4&fvtv=51062Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 112021-06-03T12:00:00Z<![CDATA[Presentation and conference call will include topline data from all cohorts]]>https://www.globenewswire.com/news-release/2021/05/26/2236360/0/en/Equillium-to-Present-at-the-Jefferies-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=51062Equillium to Present at the Jefferies Virtual Healthcare Conference2021-05-26T12:00:00Z<![CDATA[LA JOLLA, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the Jefferies Virtual Healthcare Conference taking place June 1 – 4, 2021.]]>https://www.globenewswire.com/news-release/2021/05/17/2230659/0/en/Equillium-Presents-Multiple-Posters-at-the-104th-Annual-Meeting-of-the-American-Association-of-Immunologists.html?f=22&fvtc=4&fvtv=51062Equillium Presents Multiple Posters at the 104th Annual Meeting of the American Association of Immunologists2021-05-17T12:00:00Z<![CDATA[Research highlights itolizumab’s novel mechanism of action and its effect on modulating T cell responses through inhibition of the CD6-ALCAM pathway]]>https://www.globenewswire.com/news-release/2021/05/13/2229457/0/en/Equillium-Reports-First-Quarter-2021-Financial-Results-and-Provides-Clinical-Development-Update.html?f=22&fvtc=4&fvtv=51062Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update2021-05-13T20:02:00Z<![CDATA[Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus]]>https://www.globenewswire.com/news-release/2021/05/13/2229040/0/en/Equillium-Announces-Oral-Presentation-Highlighting-Positive-Data-from-the-EQUATE-Study-in-Acute-Graft-Versus-Host-Disease-at-the-EHA2021-Virtual-Congress-of-the-European-Hematology.html?f=22&fvtc=4&fvtv=51062Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association2021-05-13T12:00:00Z<![CDATA[LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that an abstract highlighting positive data from the EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted for oral presentation at EHA2021 Virtual Congress. The annual meeting of the European Hematology Association will be held virtually June 9 – 17, 2021.]]>